Key result
PDE-5 inhibitors linked to ~37% reduction in pulmonary vascular resistance in cohort analysis.
Why the study?
Does treatment with phosphodiesterase 5 inhibitors improve hemodynamics and survival in patients with combined post- and precapillary pulmonary hypertension and HFpEF?
Cohort (n=98)
Yes
Does treatment with phosphodiesterase 5 inhibitors improve hemodynamics and survival in patients with combined post- and precapillary pulmonary hypertension and HFpEF?
Answers are grounded in this paper and cite their sources.
In patients with CpcPH and HFpEF, a severe precapillary component impairs prognosis, and PDE5i treatment may significantly improve pulmonary hemodynamics.
Combined post‐ and precapillary pulmonary hypertension (CpcPH) comprises the most severe form of postcapillary PH. A severe precapillary component (pulmonary vascular resistance [PVR] > 5 WU) is critical for therapeutic decisions. Current treatment guidelines focus on optimizing underlying cardiac disease, while there are conflicting data regarding the efficacy and safety of pulmonary arterial hypertension (PAH) drugs in selected patients. This study examines the impact of PVR > 5 WU on survival in heart failure with preserved ejection fraction (HFpEF) and CpcPH and evaluates the effect of treatment with phosphodiesterase 5 inhibitors (PDE5is) on clinical and hemodynamic parameters and on prognosis. The Hellenic Pulmonary Hypertension Registry (HOPE) enrolls patients from all PH groups in Greece. This study focuses on Group 2 CpcPH patients with HFpEF. Propensity score matching was performed to reduce the risk of bias in the treatment selection and potential confounders. Kaplan–Meier curve was used to estimate 5‐year survival, and the log‐rank test was used for the comparisons. A total of 98 patients were included, with a median follow‐up of 2.9 years. PVR > 5 WU and age were independently associated with worse survival ([HR 2.15, 95% CI 1.13–4.83, p = 0.04], [HR 1.07, 95% CI 1.03–1.13, p = 0.003], respectively). Propensity‐matched cohort analysis indicated that PDE5i treatment was associated with a significant reduction in PVR at follow‐up (from median [IQR] 4.89 [1.9] WU to 3.1 [2.0] WU, p = 0.04) and a trend towards improved survival. Severe precapillary component is associated with impaired prognosis in CpcPH. While PDE5i treatment shows promise in improving hemodynamic outcomes, its effect on long‐term survival requires further investigation.
No takes yet. Share an insight, caveat, or question.
Papadopoulos et al. (2025) conducted a cohort in Combined post- and precapillary pulmonary hypertension (CpcPH) with heart failure with preserved ejection fraction (HFpEF) (n=98). Phosphodiesterase 5 inhibitors (PDE5is) vs. Baseline (pre-treatment) or no PDE5i was evaluated on Pulmonary vascular resistance (PVR) at follow-up (p=0.04). Phosphodiesterase 5 inhibitor treatment reduced pulmonary vascular resistance from 4.89 to 3.1 WU, while a severe precapillary component (PVR > 5 WU) was associated with worse survival.
Synapse has enriched 10 related papers. Consider them for comparative context: